“Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2”, J of Skin, vol. 7, no. 2, p. s136, Mar. 2023, doi: 10.25251/skin.7.supp.136.